K-V Pharmaceutical Company Announces Comprehensive Patient Assistance Program for Makenaâ„¢

Bio-Medicine.Org

ST. LOUIS, March 8, 2011 /PRNewswire/ -- K-V Pharmaceutical Company (NYSE: KVa/KVb) (the "Company"), a specialty pharmaceutical company, along with its branded subsidiary, Ther-Rx Corporation, today announced the details of its patient assistance program for Makena [1]™ -eligible patients. Makena will be available for prescribing the week of March 14.

"Prior to FDA approval of Makena, women who could benefit from therapy may have faced barriers to access due to the absence of a commercially-available, FDA-approved product," said Greg Divis, Chief Executive Officer, K-V Pharmaceutical Company and President, Ther-Rx Corporation. "We established this comprehensive patient assistance program as part of our commitment to ensure that all eligible women have access to FDA-approved Makena."

The patient assistance program for Makena covers both uninsured and insured patients, and is based on income eligibility requirements. The program has been designed with the following guidelines in place:
Insured patients with annual household incomes of up to $100,000 who apply for and are eligible for copay assistance will have a copay of $20 or less per injection for Makena.**Uninsured patients** with annual household incomes of up to $60,000 who apply for and are eligible for patient assistance will receive Makena at no cost. Uninsured patients with annual household incomes between $60,000 and $100,000 will be able to acquire Makena at a cost that is comparable to the average copay assigned by commercial insurance plans.

The patient assistance program is available as part of the services provided by the Makena Care Connection™, a comprehensive pro
'/>"/>

SOURCE [2]

Source URL (retrieved on *04/24/2014 - 3:22am*):
http://www.mdtmag.com/news/2011/03/k-v-pharmaceutical-company-announces-comprehensive-patient-assistance-program-makena%C3%A2%E2%80%9E%C2%A2

Links:
[1] http://www.prnewswire.com/news-releases/fda-approves-makena-the-first-and-only-treatment-to-reduce-the-risk-of-preterm-birth-in-women-with-a-singleton-pregnancy-who-have-a-history-of-singleton-spontaneous-preterm-birth-115271964.html

[2] http://www.bio-medicine.org/medicine-technology-1/K-V-Pharmaceutical-Company-Announces-Comprehensive-Patient-Assistance-Program-for-Makena-u2122-15332-1/